These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38609667)

  • 1. Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.
    Jarius S; Ringelstein M; Schanda K; Ruprecht K; Korporal-Kuhnke M; Viehöver A; Hümmert MW; Schindler P; Endmayr V; Gastaldi M; Trebst C; Franciotta D; Aktas O; Höftberger R; Haas J; Komorowski L; Paul F; Reindl M; Wildemann B
    J Neurol; 2024 Jul; 271(7):4660-4671. PubMed ID: 38609667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.
    Jarius S; Pellkofer H; Siebert N; Korporal-Kuhnke M; Hümmert MW; Ringelstein M; Rommer PS; Ayzenberg I; Ruprecht K; Klotz L; Asgari N; Zrzavy T; Höftberger R; Tobia R; Buttmann M; Fechner K; Schanda K; Weber M; Asseyer S; Haas J; Lechner C; Kleiter I; Aktas O; Trebst C; Rostasy K; Reindl M; Kümpfel T; Paul F; Wildemann B;
    J Neuroinflammation; 2020 Sep; 17(1):261. PubMed ID: 32883348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
    Jarius S; Lechner C; Wendel EM; Baumann M; Breu M; Schimmel M; Karenfort M; Marina AD; Merkenschlager A; Thiels C; Blaschek A; Salandin M; Leiz S; Leypoldt F; Pschibul A; Hackenberg A; Hahn A; Syrbe S; Strautmanis J; Häusler M; Krieg P; Eisenkölbl A; Stoffels J; Eckenweiler M; Ayzenberg I; Haas J; Höftberger R; Kleiter I; Korporal-Kuhnke M; Ringelstein M; Ruprecht K; Siebert N; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; Rostásy K;
    J Neuroinflammation; 2020 Sep; 17(1):262. PubMed ID: 32883358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
    Mariotto S; Ferrari S; Monaco S; Benedetti MD; Schanda K; Alberti D; Farinazzo A; Capra R; Mancinelli C; De Rossi N; Bombardi R; Zuliani L; Zoccarato M; Tanel R; Bonora A; Turatti M; Calabrese M; Polo A; Pavone A; Grazian L; Sechi G; Sechi E; Urso D; Delogu R; Janes F; Deotto L; Cadaldini M; Bianchi MR; Cantalupo G; Reindl M; Gajofatto A
    J Neurol; 2017 Dec; 264(12):2420-2430. PubMed ID: 29063242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
    Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
    Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
    Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria.
    Forcadela M; Rocchi C; San Martin D; Gibbons EL; Wells D; Woodhall MR; Waters PJ; Huda S; Hamid S
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37977848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
    Jarius S; Paul F; Aktas O; Asgari N; Dale RC; de Seze J; Franciotta D; Fujihara K; Jacob A; Kim HJ; Kleiter I; Kümpfel T; Levy M; Palace J; Ruprecht K; Saiz A; Trebst C; Weinshenker BG; Wildemann B
    J Neuroinflammation; 2018 May; 15(1):134. PubMed ID: 29724224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.
    López-Chiriboga AS; Majed M; Fryer J; Dubey D; McKeon A; Flanagan EP; Jitprapaikulsan J; Kothapalli N; Tillema JM; Chen J; Weinshenker B; Wingerchuk D; Sagen J; Gadoth A; Lennon VA; Keegan BM; Lucchinetti C; Pittock SJ
    JAMA Neurol; 2018 Nov; 75(11):1355-1363. PubMed ID: 30014148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
    Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
    J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
    J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].
    Jarius S; Paul F; Aktas O; Asgari N; Dale RC; de Seze J; Franciotta D; Fujihara K; Jacob A; Kim HJ; Kleiter I; Kümpfel T; Levy M; Palace J; Ruprecht K; Saiz A; Trebst C; Weinshenker BG; Wildemann B
    Nervenarzt; 2018 Dec; 89(12):1388-1399. PubMed ID: 30264269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis. A brief review].
    Jarius S; Wildemann B
    Nervenarzt; 2021 Apr; 92(4):317-333. PubMed ID: 33787942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
    Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.